A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A Trial of the Eastern Cooperative Oncology Group

Cancer Investigation

Volumn 24, Issue 7, 2006, Pages 677-681

  Carlson, Robert W ^a   O'Neill, Anne M ^b   Goldstein, Lori J ^c   Sikic, Branimir I ^a   Abramson, Neil ^d   Stewart, James A ^e   Davidson, Nancy E ^f   Wood, William C ^g  

^a STANFORD UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d Baptist Cancer Institute   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g EMORY UNIVERSITY   (United States)

Author keywords

Breast neoplasms; Multidrug resistance; Paclitaxel; Valdospar

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; VALSPODAR;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ATAXIA; BLEEDING; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE TIME EFFECT RELATION; DYSMETRIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NEUROTOXICITY; PAIN; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOSPORINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; PACLITAXEL; PILOT PROJECTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33751501999     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600981349     Document Type: Article

References (25)

1. Goldstein, L.J.; Galski, H.; Fojo, A.; Willingham, M.; Lai, S. L.; Gazdar, A.; et al. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 1989, 81, 116-124.
2. Goldstein, L.J.; Pastan, I.; Gottesman, M.M.; Multidrug resistance in human cancer. Crit Rev Oncol Hematol. 1992, 12, 243-253.
3. Sikic, B. Modulation ofmultidrug resistance: at the threshold. J Clin Oncol. 1993, 11, 1629-1635.
4. Sikic, B.I.; Fisher, G.A.; Lum, B.L.; Halsey, J.; Beketic-Oreskovic, L.; Chen, G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997, 40 (Suppl), S13-S19.
5. Jachez, B.; Nordmann, R.; Loor, F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. Journal of the National Cancer Institute. 1993, 85, 478-446.
6. Boesch, D.; Gaveriaux, C.; Jachez, B.; Pourtier-Manzanedo, A.; Bollinger, P.; Loor, F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991, 51, 4226-4233.
7. Twentymann, P.R.; Bleehen, N.M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected][published erratum appears in European Journal Cancer 1992;28:616]. European Journal of Cancer. 1992, 27, 1639-1642.
8. Fracasso, P.M.; Fisher, G.A.; Wiehl, J.G.; Collins, H.; Hausdorff, J.; Williams, K.M.; Halsey, J.; Pearce, T.E.; Sikic, B.I. Phase I trial of paclitaxel (Taxol) and SDZ PSC 833 in patients with solid tumors. Proc Am Soc Clin Oncol. 1995, 14.
9. Collins, H.L.; Fisher, G.A.; Hausdorff, J.; Lum, B.L.; Pearce, T.; Halsey, J.; Sikic, B.I. Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc Am Soc Clin Oncol. 1995, 14,
10. Schiller, J.H.; Storer, B.; Tutsch, K.; Arzoomanian, R.; Alberti, D.; Feierabend, C.; Spriggs, D. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994, 12, 241-248.
11. Seidman, A.; Tiersten, A.; Hudis, C.; Gollub, M.; Barrett, S.; Yao, T.; Lepore, J.; Gilewski, T.; Currie, V.; Crown, J. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995, 13, 2575-2581.
12. Sledge Jr, G.W.; Neuberg, D.; Ingle, J.; Martino, S. and Wood, W. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol. 1997, 16, 1a.
13. Holmes, F.A.; Valero, V.; Buzdar, A.U.; Booser, D.J.; Winn, R.; Tolcher, A.; et al. Final results: randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (pt) with met breast cancer (mbc). The long & short of it. Proc Am Soc Clin Oncol. 1998, 17, 110a.
14. Smith, R.E.; Brown, A.M.; Mamounas, E.P.; Anderson, S.J.; Lembersky, B.C.; Atkins, J.H.; et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B- 26. J Clin Oncol. 1999, 17, 3403-3411.
15. Perez, E.A.; Vogel, C.L.; Irwin, D.H.; Kirshner, J.J.; Patel, R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001, 19, 4216-4223.
16. Reichman, B.S.; Seidman, A.D.; Crown, J.P.; Heelan, R.; Hakes, T.B.; Lebwohl, D.E.; Gilewski, T.A.; Surbone, A.; Currie, V.; Hudis, C.A.; et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1993, 11, 1943-1951.
17. Holmes, F.A.; Valero, V.; Walters, R.S.; Theriault, R.L.; Booser,D.J.; Giuseppe, F.; Buzdar, A.U.; Frye, D.; Gibbs, H.R.; Hoortobagyi, G.N. The M.D. Anderson Cancer Center experience with taxol in metastatic breast cancer. Monogr Natl Cancer Inst. 1993, 15, 161-169.
18. Sledge, G.W.; Neuberg, D.; Bernardo, P.; Ingle, J.N.; Martino, S.; Rowinsky, E.K.; Wood, W.C. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003, 21, 588-592.
19. Cox, D.R.; Snell, E.J. Analysis of Binary Data, Second Edition. London, 1989, 26-105.
20. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958, 53, 457-481.
21. Sangrajrang, S.; Fellous, A. Taxol resistance. Chemotherapy. 2000, 46, 327-334.
22. Yusuf, R.Z.; Duan, Z.; Lamendola, D.E.; Penson, R.T.; Seiden, M.V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003, 3, 1-19.
23. Trock, B.J.; Leonessa, F., and Clarke, R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997, 89, 917-931.
24. Leonessa, F., and Clarke, R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer. 2003, 10, 43-73.
25. Fracasso, P.M.; Brady, M.F.; Moore, D.H.; Walker, J.L.; Rose, P.G.; Letvak, L.; Grogan, T.M.; McGuire, W.P. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol. 2001, 19, 2975-2982.